153 related articles for article (PubMed ID: 36240474)
41. Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial.
de Boer SM; Powell ME; Mileshkin L; Katsaros D; Bessette P; Haie-Meder C; Ottevanger PB; Ledermann JA; Khaw P; D'Amico R; Fyles A; Baron MH; Jürgenliemk-Schulz IM; Kitchener HC; Nijman HW; Wilson G; Brooks S; Gribaudo S; Provencher D; Hanzen C; Kruitwagen RF; Smit VTHBM; Singh N; Do V; Lissoni A; Nout RA; Feeney A; Verhoeven-Adema KW; Putter H; Creutzberg CL;
Lancet Oncol; 2019 Sep; 20(9):1273-1285. PubMed ID: 31345626
[TBL] [Abstract][Full Text] [Related]
42. Overview of adjuvant radiotherapy on survival, failure pattern and toxicity in stage I to II endometrial carcinoma: a long-term multi-institutional analysis in China.
Wang W; Wang T; Liu Z; He J; Sun X; Zhong W; Zhao F; Li X; Li S; Zhu H; Ma Z; Hu K; Zhang F; Hou X; Wei L; Zou L
BMC Cancer; 2022 Mar; 22(1):266. PubMed ID: 35287626
[TBL] [Abstract][Full Text] [Related]
43. The prognostic significance of estrogen and progesterone receptors in grade I and II endometrioid endometrial adenocarcinoma: hormone receptors in risk stratification.
Guan J; Xie L; Luo X; Yang B; Zhang H; Zhu Q; Chen X
J Gynecol Oncol; 2019 Jan; 30(1):e13. PubMed ID: 30479097
[TBL] [Abstract][Full Text] [Related]
44. Adjuvant radiation therapy is associated with improved overall survival in high-intermediate risk stage I endometrial cancer: A national cancer data base analysis.
Gupta V; McGunigal M; Prasad-Hayes M; Kalir T; Liu J
Gynecol Oncol; 2017 Jan; 144(1):119-124. PubMed ID: 27793358
[TBL] [Abstract][Full Text] [Related]
45. Adjuvant vaginal brachytherapy alone for high risk localized endometrial cancer as defined by the three major randomized trials of adjuvant pelvic radiation.
McCloskey SA; Tchabo NE; Malhotra HK; Odunsi K; Rodabaugh K; Singhal P; Lele S; Jaggernauth W
Gynecol Oncol; 2010 Mar; 116(3):404-7. PubMed ID: 19944453
[TBL] [Abstract][Full Text] [Related]
46. Is the extent of lymphadenectomy a prognostic factor in International Federation of Gynecology and Obstetrics stage II endometrioid endometrial cancer?
Cuylan ZF; Akilli H; Gungorduk K; Demirkiran F; Oz M; Salman MC; Sozen H; Celik H; Gokcu M; Bese T; Meydanli MM; Ozgul N; Topuz S; Kuscu E; Kuru O; Gokmen S; Gultekin M; Ayhan A
J Obstet Gynaecol Res; 2021 Mar; 47(3):1134-1144. PubMed ID: 33426779
[TBL] [Abstract][Full Text] [Related]
47. Survival outcomes of women with grade 3 endometrioid endometrial cancer: the impact of adjuvant treatment strategies.
Gungorduk K; Muallem J; Aşıcıoğlu O; Gülseren V; Güleç ÜK; Meydanlı MM; Sehouli J; Özdemir A; Şahin H; Khatib G; Miranda A; Boran N; Şenol T; Yıldırım N; Turan T; Oge T; Taşkın S; Vardar MA; Ayhan A; Muallem MZ
Arch Gynecol Obstet; 2022 Mar; 305(3):671-681. PubMed ID: 34448946
[TBL] [Abstract][Full Text] [Related]
48. Mixed clear cell/endometrioid and clear cell/serous carcinoma of the uterus are clinicopathologically similar to pure clear cell carcinoma: An NRG Oncology/Gynecologic Oncology Group (GOG-210) study of 311 women.
Hagemann IS; Deng W; Zaino RJ; Powell MA; Gunderson Jackson C; Cosgrove C; Mathews C; Pearl ML; Waggoner S; Ghebre R; Lele S; Guntupalli S; Secord AA; Ioffe O; Rasty G; Singh M; Soslow R; Creasman W; Mutch DG
Gynecol Oncol; 2023 Oct; 177():38-45. PubMed ID: 37634258
[TBL] [Abstract][Full Text] [Related]
49. FGFR2c Mesenchymal Isoform Expression Is Associated with Poor Prognosis and Further Refines Risk Stratification within Endometrial Cancer Molecular Subtypes.
Sengal AT; Patch AM; Snell CE; Smith DS; Leung SCY; Talhouk A; Williams ED; McAlpine JN; Pollock PM
Clin Cancer Res; 2020 Sep; 26(17):4569-4580. PubMed ID: 32414751
[TBL] [Abstract][Full Text] [Related]
50. [Molecular-integrated risk profile: An opportunity for therapeutic de-escalation in intermediate and high-intermediate risk endometrial cancer].
Espenel S; Pointreau Y; Genestie C; Durdux C; Haie-Meder C; Chargari C
Cancer Radiother; 2022 Oct; 26(6-7):931-937. PubMed ID: 36031498
[TBL] [Abstract][Full Text] [Related]
51. Treatment outcomes of patients with stage II pure endometrioid-type endometrial cancer: a Taiwanese Gynecologic Oncology Group (TGOG-2006) retrospective cohort study.
Fu HC; Chen JR; Chen MY; Hsu KF; Cheng WF; Chiang AJ; Ke YM; Chen YC; Chang YY; Huang CY; Kang CY; Kan YY; Hsiao SM; Yen MS
J Gynecol Oncol; 2018 Sep; 29(5):e76. PubMed ID: 30022636
[TBL] [Abstract][Full Text] [Related]
52. Long non-coding RNA profiling links subgroup classification of endometrioid endometrial carcinomas with trithorax and polycomb complex aberrations.
Jiang Y; Malouf GG; Zhang J; Zheng X; Chen Y; Thompson EJ; Weinstein JN; Yuan Y; Spano JP; Broaddus R; Tannir NM; Khayat D; Lu KH; Su X
Oncotarget; 2015 Nov; 6(37):39865-76. PubMed ID: 26431491
[TBL] [Abstract][Full Text] [Related]
53. Discriminating miRNA Profiles between Endometrioid Well- and Poorly-Differentiated Tumours and Endometrioid and Serous Subtypes of Endometrial Cancers.
Kalinkova L; Kajo K; Karhanek M; Wachsmannova L; Suran P; Zmetakova I; Fridrichova I
Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32842533
[TBL] [Abstract][Full Text] [Related]
54. Lack of association between deficient mismatch repair expression and outcome in endometrial carcinomas of the endometrioid type.
Ruiz I; Martín-Arruti M; Lopez-Lopez E; Garcia-Orad A
Gynecol Oncol; 2014 Jul; 134(1):20-3. PubMed ID: 24814467
[TBL] [Abstract][Full Text] [Related]
55. Clinicopathologic Evaluation of CTNNB1 Mutations in High-Intermediate Risk Endometrial Endometrioid Carcinoma.
Haag JG; Wolsky RJ; Moroney MR; Sheren J; Sheeder J; Bitler BG; Corr BR
Int J Gynecol Pathol; 2023 Jan; 42(1):43-53. PubMed ID: 35283443
[TBL] [Abstract][Full Text] [Related]
56. Spatial expression of the FGFR2b splice isoform and its prognostic significance in endometrioid endometrial carcinoma.
Sengal AT; Smith D; Snell CE; Leung S; Talhouk A; Williams ED; McAlpine JN; Pollock PM
J Pathol Clin Res; 2022 Nov; 8(6):521-537. PubMed ID: 35866380
[TBL] [Abstract][Full Text] [Related]
57. Prognostic Significance of POLE Exonuclease Domain Mutations in High-Grade Endometrioid Endometrial Cancer on Survival and Recurrence: A Subanalysis.
Billingsley CC; Cohn DE; Mutch DG; Hade EM; Goodfellow PJ
Int J Gynecol Cancer; 2016 Jun; 26(5):933-8. PubMed ID: 26937754
[TBL] [Abstract][Full Text] [Related]
58. Clinical impact of genetic alterations of CTNNB1 in patients with grade 3 endometrial endometrioid carcinoma.
Kobayashi Kato M; Asami Y; Takayanagi D; Matsuda M; Shimada Y; Hiranuma K; Kuno I; Komatsu M; Hamamoto R; Matsumoto K; Ishikawa M; Kohno T; Kato T; Shiraishi K; Yoshida H
Cancer Sci; 2022 May; 113(5):1712-1721. PubMed ID: 35278272
[TBL] [Abstract][Full Text] [Related]
59. Clinical outcomes of patients with POLE mutated endometrioid endometrial cancer.
Stasenko M; Tunnage I; Ashley CW; Rubinstein MM; Latham AJ; Da Cruz Paula A; Mueller JJ; Leitao MM; Friedman CF; Makker V; Soslow RA; DeLair DF; Hyman DM; Zamarin D; Alektiar KM; Aghajanian CA; Abu-Rustum NR; Weigelt B; Cadoo KA
Gynecol Oncol; 2020 Jan; 156(1):194-202. PubMed ID: 31757464
[TBL] [Abstract][Full Text] [Related]
60. The brave new world of endometrial cancer : Future implications for adjuvant treatment decisions.
Marnitz S; Waltar T; Köhler C; Mustea A; Schömig-Markiefka B
Strahlenther Onkol; 2020 Nov; 196(11):963-972. PubMed ID: 32430662
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]